NewAmsterdam Pharma to Present at the 2025 RBCCM Global Healthcare Conference
NewAmsterdam Pharma (Nasdaq: NAMS), a late-stage clinical biopharmaceutical company focused on developing oral, non-statin medicines for cardiovascular disease patients with elevated LDL-C, has announced its participation in the 2025 RBCCM Global Healthcare Conference. Ian Somaiya, the company's Chief Financial Officer, will engage in a fireside chat on Tuesday, May 20, 2025, at 10:00 a.m. ET. The presentation will be accessible via live webcast through NewAmsterdam's investor relations website, with an archived replay available afterward.
NewAmsterdam Pharma (Nasdaq: NAMS), un'azienda biofarmaceutica in fase avanzata di sviluppo clinico, specializzata nella creazione di farmaci orali non a base di statine per pazienti con malattie cardiovascolari e livelli elevati di LDL-C, ha annunciato la sua partecipazione alla 2025 RBCCM Global Healthcare Conference. Ian Somaiya, Chief Financial Officer dell'azienda, parteciperà a una conversazione informale il martedì 20 maggio 2025 alle 10:00 ET. La presentazione sarà disponibile in diretta streaming sul sito web delle relazioni con gli investitori di NewAmsterdam, con una registrazione accessibile successivamente.
NewAmsterdam Pharma (Nasdaq: NAMS), una empresa biofarmacéutica en etapa avanzada centrada en desarrollar medicamentos orales no estatinas para pacientes con enfermedades cardiovasculares y niveles elevados de LDL-C, ha anunciado su participación en la Conferencia Global de Salud RBCCM 2025. Ian Somaiya, director financiero de la compañía, participará en una charla informal el martes 20 de mayo de 2025 a las 10:00 a.m. ET. La presentación estará disponible vía webcast en vivo a través del sitio web de relaciones con inversores de NewAmsterdam, con una repetición archivada disponible posteriormente.
NewAmsterdam Pharma(나스닥: NAMS)는 고도 LDL-C 환자를 위한 경구용 비스타틴 심혈관 질환 치료제 개발에 주력하는 후기 임상 단계의 바이오제약 회사로, 2025 RBCCM 글로벌 헬스케어 컨퍼런스에 참여한다고 발표했습니다. 회사의 최고재무책임자(CFO) Ian Somaiya는 2025년 5월 20일 화요일 오전 10시(동부시간)에 파이어사이드 채팅에 참여할 예정입니다. 발표는 NewAmsterdam 투자자 관계 웹사이트를 통해 라이브 웹캐스트로 시청할 수 있으며, 이후 녹화 재생도 제공됩니다.
NewAmsterdam Pharma (Nasdaq : NAMS), une société biopharmaceutique en phase clinique avancée, spécialisée dans le développement de médicaments oraux non statines pour les patients atteints de maladies cardiovasculaires avec un taux élevé de LDL-C, a annoncé sa participation à la Conférence mondiale RBCCM sur la santé 2025. Ian Somaiya, directeur financier de l'entreprise, prendra part à une discussion informelle le mardi 20 mai 2025 à 10h00 ET. La présentation sera accessible en direct via un webcast sur le site des relations investisseurs de NewAmsterdam, avec un replay disponible par la suite.
NewAmsterdam Pharma (Nasdaq: NAMS), ein biopharmazeutisches Unternehmen in der späten klinischen Phase, das sich auf die Entwicklung oraler, nicht-statinbasierter Medikamente für Herz-Kreislauf-Patienten mit erhöhtem LDL-C konzentriert, hat seine Teilnahme an der 2025 RBCCM Global Healthcare Conference angekündigt. Ian Somaiya, der Finanzvorstand des Unternehmens, wird am Dienstag, den 20. Mai 2025, um 10:00 Uhr ET an einem Fireside-Chat teilnehmen. Die Präsentation wird live per Webcast auf der Investor-Relations-Website von NewAmsterdam verfügbar sein, mit einer anschließenden Archiv-Wiedergabe.
- None.
- None.
NAARDEN, The Netherlands and MIAMI, May 14, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that Ian Somaiya, Chief Financial Officer of NewAmsterdam Pharma, will participate in a fireside chat at the 2025 RBCCM Global Healthcare Conference on Tuesday, May 20, 2025 at 10:00 a.m. ET.
A live webcast of the fireside chat will be available through the investor relations section of the NewAmsterdam Pharma website at ir.newamsterdampharma.com. Following the live webcast, an archived replay will be available on the Company’s website.
About NewAmsterdam
NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple phase 3 trials, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated.
Company Contact
Matthew Philippe
P: 1-917-882-7512
matthew.philippe@newamsterdampharma.com
Media Contact
Spectrum Science on behalf of NewAmsterdam
Jaryd Leady
P: 1-856-803-7855
jleady@spectrumscience.com
Investor Contact
Precision AQ on behalf of NewAmsterdam
Austin Murtagh
P: 1-212-698-8696
austin.murtagh@precisionaq.com
FAQ
When is NewAmsterdam Pharma (NAMS) presenting at the 2025 RBCCM Global Healthcare Conference?
Who will represent NewAmsterdam Pharma (NAMS) at the 2025 RBCCM Healthcare Conference?
How can investors watch NewAmsterdam Pharma's (NAMS) presentation at the RBCCM conference?
What is NewAmsterdam Pharma's (NAMS) main focus in drug development?
